Copernicium Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.60 Cr
as on 07-07-2024
- Paid Up Capital ₹ 3.58 Cr
as on 07-07-2024
- Company Age 11 Year, 10 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 29.21 Cr
as on 07-07-2024
- Revenue -13.78%
(FY 2022)
- Profit 4.34%
(FY 2022)
- Ebitda 20.27%
(FY 2022)
- Net Worth 173.61%
(FY 2022)
- Total Assets 11.47%
(FY 2022)
About Copernicium Pharmaceuticals
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.60 Cr and a paid-up capital of Rs 3.58 Cr.
The company currently has active open charges totaling ₹29.21 Cr.
Akash Puranik and Salim Shaikh serve as directors at the Company.
- CIN/LLPIN
U24230KA2013PTC072419
- Company No.
072419
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Dec 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Copernicium Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akash Puranik  | Director | 23-Dec-2013 | Current |
| Salim Shaikh | Director | 10-Dec-2013 | Current |
Financial Performance and Corporate Structure Insights of Copernicium Pharmaceuticals.
Copernicium Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 13.78% decrease. The company also saw a slight improvement in profitability, with a 4.34% increase in profit. The company's net worth Soared by an impressive increase of 173.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Copernicium Pharmaceuticals?
In 2021, Copernicium Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Symbio Generrics India Private LimitedActive 13 years 6 monthsAkash Puranik and Salim Shaikh are mutual person
- Symbio Natural Products Private LimitedActive 7 years 1 month
Akash Puranik and Salim Shaikh are mutual person
Vpl Chemicals Private LimitedActive 25 years 24 daysAkash Puranik and Salim Shaikh are mutual person
Sequent Penems Private LimitedActive 14 years 7 monthsAkash Puranik and Salim Shaikh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Nov 2022 | ₹28.00 Cr | Open |
Hdfc Bank Limited Creation Date: 01 Sep 2021 | ₹2.97 M | Open |
Hdfc Bank Limited Creation Date: 16 Sep 2020 | ₹1.00 M | Open |
How Many Employees Work at Copernicium Pharmaceuticals?
Copernicium Pharmaceuticals has a workforce of 8 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Copernicium Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Copernicium Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
